Extent of pharmacovigilance among resident doctors in Edo and Lagos states of Nigeria

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 2, 2010, Pages 191-195

  Ohaju Obodo, J O ^a   Iribhogbe, O I ^a  

^a AMBROSE ALLI UNIVERSITY   (Nigeria)

Author keywords

Adverse drug reactions; Pharmacovigilance; Spontaneous reporting

Indexed keywords

ARTICLE; DRUG SURVEILLANCE PROGRAM; HEALTH CARE QUALITY; HEALTH CENTER; HEALTH SURVEY; HUMAN; MEDICAL EDUCATION; NIGERIA; PHYSICIAN; PRIORITY JOURNAL;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; BENIN; CROSS-SECTIONAL STUDIES; HUMANS; INTERNSHIP AND RESIDENCY; NIGERIA; QUESTIONNAIRES;

EID: 76149110122     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1724     Document Type: Article

References (19)

1. Randell T. Thalidomide's back in the news, but in more favourable circumstances. JAMA 1990; 263: 467-468.
2. Alvarez-Requejo A, Carvalja A, Begaud B, et al. Under-reporting of adverse drug reactions-estimate based on a spontaneous reporting schema and a sentinel system. Eur J Clin Pharmacol 1998; 54: 483-488.
3. WHO Geneva. The importance of pharmacovigilance, safety monitoring of medicinal products; technical report series 2002; 4-7.
4. Skegg DCG. Pitfalls of pharmacoepidemiology. Br Med J 2002; 321: 1171-1172 PubMed.
5. Biriell C, Edwards IR. Reasons for Reporting ADR-Some thoughts based on an International Review. Pharmacoepidemiol Drug Saf 1997; 6: 21-26.
6. Goodwin JS. The empirical basis for the discovery of new therapies. Persp Biol Med 2002; 35: 20-36 PubMed.
7. NAFDAC, Nigeria. Safety of Medicine in Nigeria; a guide for detecting and reporting adverse drug reactions. 2004; 11-27.
8. Rawlins MD, Wood SM. Attitudinal survey of ADR reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 1995; 53-57.
9. Belton KJ. Attitude Survey of adverse drug reaction reporting by health care professionals across the European Union. The European Pharma-covigilance Research Group. Eur J Clin Pharmacol 1995; 52: 423-427.
10. Hasford J, Goettler M, Munter KH, et al. Physicians knowledge and attitude regarding the spontaneous reporting system for ADR. J Clin Epidemiol 2002; 55: 945-950.
11. Figueiras A, Tato F, Fontainas JBS, et al. Influence of physicians attitudes on reporting adverse drug events: a case-control study. Medical Care Journal 1999; 37(8): 809-814.
12. Venning GR. Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms. Br Med J 1982; 284: 249-252.
13. Stiker B, Psaty B. Detection, verification and quantification of adverse drug reactions. Br Med J 2004; 329: 44-47.
14. Suparna C, Nazmun L, Seuvick G. A survey of the knowledge, attitude and practice of adverse drug reaction reporting by clinicians in eastern India. Drug Saf 2006; 29: (7), 641.
15. Routledge P. 150 years of pharmacovigilance. Lancet 1998; 301: 200-201.
16. Olsson S. The role of the WHO programme on international drug monitoring in co-ordinating world wide drug safety efforts. Drug Saf 1998; 19: 1-10.
17. Mark G. Drug safety on trial. EMBO reports 2005; 6: (3), 202.
18. Wiholm BE, Olsson S, Moore N, Waller P. Spontaneous reporting system outside the United States. In Pharmaco-epidemiology, 3rd edition, Strom BL (ed.). Chichester Wiley, 2000; 175-190.
19. Zoriah A, Tan CS, Nurul SB. Reporting of adverse drug reactions; prediction of under-reporting in Malaysia. Pharmacoepidemiol Drug Saf 2007; 16 (2), 223.